Effect of Endothelin-1 on Erythropoietin Production in a Rat Model Under Normoxia and Functional Carbon Monoxide-induced Hypoxia

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2006 Aug 10

PMID 16896802

Authors

A Grenz

J Klein

C Kohle

S Freudenthaler

B Proksch

J Wu

S Wolf

H Osswald

C H Gleiter

Affiliations

Soon will be listed here.

Abstract

It has been hypothesized that autacoids, such as endothelin-1 (ET), may modulate erythropoietin (Epo) secretion. Therefore, we studied the effect of ET-1 infusion and of a nonselective ET(A/B) receptor antagonist on Epo secretion under carbon monoxide (CO) exposure. Anesthetized rats were supplied with room temperature air containing increasing concentrations of CO by an aerating cap. A CO-Epo dose-response curve over the range of 0.02-0.14 vol% CO was conducted. Subpressor doses of ET-1 (3 pmol/min/kg BW) and the ET(A/B) receptor antagonist LU302872 (LU; 30 mg/kg) were applied to anaesthetized rats under normoxia (controls CON, ET, LU) and following hypoxia (CO exposure; H-CON, H-ET, H-LU). Mean arterial blood pressure (MAP), glomerular filtration rate (GFR, inulin clearance), Epo and ET-1 serum concentrations (ELISA) and renal Epo mRNA (Light Cycler) were determined. The EC50 value for CO was 0.1 vol% with a 70-fold increase in Epo serum concentrations. CO exposure increased Epo serum and Epo mRNA concentrations in the expected range in all groups. None of the treatments with ET or LU influenced the effect of hypoxia on Epo serum concentrations and renal Epo mRNA content. Under hypoxia, administration of ET-1 as well as LU prevented the hypoxia-induced decrease in MAP (p<0.05). Under hypoxia, GFR was reduced by 50% except for H-LU with values comparable to normoxia. Taken together, the influence of hypoxia exceeds by far the effect of ET-1 on Epo production, irrespective of the presence or absence of exogenous ET-1. Thus, ET-1 does not appear to be a major modulator of Epo production.

References

Ritthaler T, Gopfert T, Firth J, Ratcliffe P, Kramer B, Kurtz A . Influence of hypoxia on hepatic and renal endothelin gene expression. Pflugers Arch. 1996; 431(4):587-93. DOI: 10.1007/BF02191907. View

Takabatake T, Ise T, Ohta K, Kobayashi K . Effects of endothelin on renal hemodynamics and tubuloglomerular feedback. Am J Physiol. 1992; 263(1 Pt 2):F103-8. DOI: 10.1152/ajprenal.1992.263.1.F103. View

Wolf S, Gaschler F, Brehm S, Klaussner M, Amann K, Risler T . Endothelin-receptor antagonists in uremic cardiomyopathy. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S348-50. DOI: 10.1097/00005344-200036051-00101. View

Freudenthaler S, Lucht I, Schenk T, Brink M, Gleiter C . Dose-dependent effect of angiotensin II on human erythropoietin production. Pflugers Arch. 2000; 439(6):838-44. DOI: 10.1007/s004249900238. View

Brochu E, Lacasse S, Lariviere R, Kingma I, Grose J, Lebel M . Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol. 1999; 10(7):1440-6. DOI: 10.1681/ASN.V1071440. View

Jilma B, Krejcy K, Dirnberger E, Eichler H, Kapiotis S, Dorner G . Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 1997; 60(21):1859-66. DOI: 10.1016/s0024-3205(97)00146-x. View

Goerre S, Wenk M, Bartsch P, Luscher T, Niroomand F, Hohenhaus E . Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation. 1995; 91(2):359-64. DOI: 10.1161/01.cir.91.2.359. View

AMBERG W, Hergenroder S, Hillen H, Jansen R, Kettschau G, Kling A . Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist. J Med Chem. 1999; 42(16):3026-32. DOI: 10.1021/jm9910425. View

Nir A, Clavell A, Heublein D, Aarhus L, Burnett Jr J . Acute hypoxia and endogenous renal endothelin. J Am Soc Nephrol. 1994; 4(11):1920-4. DOI: 10.1681/ASN.V4111920. View

10.

Perrella M, Edell E, Krowka M, Cortese D, Burnett Jr J . Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia. Am J Physiol. 1992; 263(1 Pt 2):R45-50. DOI: 10.1152/ajpregu.1992.263.1.R45. View

11.

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

12.

Galat J, Robinson A, Rhodes R . The contribution of hypoxia to postischemic renal dysfunction. Surgery. 1988; 104(2):257-65. View

13.

Sung C, Arleth A, Storer B, Ohlstein E . Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994; 271(1):429-37. View

14.

Barton M, Shaw S, dUscio L, Moreau P, Luscher T . Differential modulation of the renal and myocardial endothelin system by angiotensin II in Vivo. Effects of chronic selective ETA receptor blockade. J Cardiovasc Pharmacol. 1998; 31 Suppl 1:S265-8. DOI: 10.1097/00005344-199800001-00075. View

15.

Walker B . Diuretic response to acute hypoxia in the conscious dog. Am J Physiol. 1982; 243(5):F440-6. DOI: 10.1152/ajprenal.1982.243.5.F440. View

16.

Syed N, Gulmi F, CHOU S, Mooppan U, Kim H . Renal actions of endothelin-1 under endothelin receptor blockade by BE-18257B. J Urol. 1998; 159(2):563-6. DOI: 10.1016/s0022-5347(01)63984-3. View

17.

Henry D, Bowers P, Romano M, Provenzano R . Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med. 2004; 164(3):262-76. DOI: 10.1001/archinte.164.3.262. View

18.

Eckardt K, Kurtz A, Bauer C . Regulation of erythropoietin production is related to proximal tubular function. Am J Physiol. 1989; 256(5 Pt 2):F942-7. DOI: 10.1152/ajprenal.1989.256.5.F942. View

19.

Sugiura M, Inagami T, Kon V . Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun. 1989; 161(3):1220-7. DOI: 10.1016/0006-291x(89)91372-7. View

20.

Benohr P, Harsch S, Proksch B, Gleiter C . Does angiotensin II modulate erythropoietin production in HepG2 cells?. Nephron Exp Nephrol. 2005; 98(4):e124-31. DOI: 10.1159/000081556. View